Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alanine dehydrogenase (ALD) is an enzyme that catalyzes the reversible oxidative deamination of L-alanine to pyruvate, with concurrent reduction of NAD+ to NADH. It is a homo-hexameric enzyme, widely found in bacteria, and plays a critical role in microbial carbon and nitrogen metabolism by enabling the interconversion of alanine and pyruvate for energy generation and biosynthetic reactions[1][2][4][6]. It participates in key metabolic pathways—including the tricarboxylic acid (TCA) cycle, taurine and hypotaurine metabolism, and CO2 fixation[2][3][4]. In some pathogenic bacteria, alanine dehydrogenase serves as a secreted antigen and virulence factor during infection[5]. In general, it is not a major therapeutic target in current clinical drug discovery, but its role as a microbial antigen may have diagnostic applications[5]. The enzyme is not known to interact with specific approved drugs.
Catalysis of NAD+-dependent reversible conversion of L-alanine and pyruvate via hydride transfer and deamination (targeted as an antigen/virulence factor in some bacterial pathogens)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alanine dehydrogenase (ALD).